Hormone replacement treatment choices in complete androgen insensitivity syndrome: an audit of an adult clinic

Jennifer K Y Ko, Thomas F J King, Louise Williams, Sarah M Creighton and Gerard S Conway
Department of Women’s Health, University College London Hospital, London, UK

Abstract

Objective: To review the treatment choices of women with complete androgen insensitivity syndrome (CAIS) at a single tertiary centre.

Design: Retrospective review.

Patients: Women with CAIS identified from our database.

Results: The study group comprised 141 women with CAIS. Eleven percent (16/141) of women had gonads in situ, 3 of whom were under workup for gonadectomy. The age of gonadectomy in the remainder 125 women was 17 (0.1–53) years. The most common form of HRT was oral oestrogen or transdermal oestrogen in 80% (113/141). 13/141 (9%) women used vaginal oestrogens alone or together with other forms of HRT. Testosterone preparations had been used by 17% (24/141) of women and were currently used in 10% (14/141). Of those who had used testosterone, 42% (10/24) had chosen not to continue after a therapeutic trial.

Conclusions: In a clinic offering individualised multidisciplinary care for women with CAIS, we found that the majority of women chose oestrogen-based treatment while a significant minority used testosterone.

Introduction

Complete androgen insensitivity syndrome (CAIS) is one of the most common disorders of sex development (DSD) caused by mutations of the androgen receptor gene. The estimated prevalence of AIS is 4.1 per 100,000 live born females (1). Testes develop in the presence of the Y chromosome, but the lack of androgen receptor activity results in a typical female phenotype. The anti-Mullerian hormone produced by the gonads causes regression of the uterus, cervix and proximal vagina during foetal development. Common clinical presentations include inguinal or labial hernia in childhood or primary amenorrhoea in adolescence (1). CAIS may also present through screening after a family member is affected or discordance between prenatal sex prediction and phenotype at birth (1).

Traditionally, prophylactic gonadectomy has been advised because of the risk of malignancy of the intra-abdominal testes, which ranges from 0 to 30% (2). Current practice is to recommend gonadectomy after completion of puberty (2). Hormone replacement therapy (HRT) is required after gonadectomy in order to maintain secondary sexual characteristics, bone and cardiovascular health and to promote general wellbeing and sexual function. In the study by Berglund and coworkers, 64/78 women with AIS were on HRT and the median age at first prescription of HRT was 14 years (1). Sex steroid
replacement has traditionally been based on types of oestrogen, but there is increasing interest from user groups in the use of testosterone, which in this situation is used as a prohormone providing oestradiol via aromatisation. As women with CAIS do not have a uterus, progesterone is not required.

Based on our clinical experience, interest in the use of testosterone in women with CAIS has developed through observations voiced from user groups, particularly women who experienced late gonadectomy. Unlike younger age groups, those who have gained a sense of a ‘testosterone milieu’ after gonadarche are in a good position to make a comparison with a post-gonadectomy ‘oestrogen milieu’. The reported differences between these two situations include altered vitality, libido and athletic performance. Of course, the psychosocial effects of a difficult diagnosis, which often coincides with gonadectomy, may contribute to such symptoms, and it is accepted that wellbeing is not solely hormone related.

As there are no known adverse effects of long-term exposure to testosterone in women with CAIS who have declined gonadectomy and in the absence of guidelines on the most appropriate HRT for this group of women, our clinic philosophy has been to offer choice and follow individual preference. Here, we reviewed our experience on HRT choices made by women with CAIS.

Subjects and methods

The study was a retrospective analysis of women with CAIS seen at the University College London Hospital (UCLH), a tertiary referral centre for DSD. Management is by a multidisciplinary team comprising an endocrinologist, gynaecologist, nurse specialist and clinical psychologist. The clinical diagnosis of CAIS was based on an unambiguous female phenotype, scant body hair, 46,XY karyotype, testicular histology and absent uterus (3). Androgen receptor mutation testing was not performed routinely when the clinical diagnosis was clearcut and only performed if the carrier status of sisters was in question. Women were followed up every 2–6 months at the start of hormonal therapy, and the follow-up spaced out to annual visits when stable. Side effects were asked at the start of hormonal therapy, and the follow-up spaced out to annual visits when stable. Side effects were asked at the start of hormonal therapy, and the follow-up spaced out to annual visits when stable. Side effects were asked at the start of hormonal therapy, and the follow-up spaced out to annual visits when stable. Side effects were asked at the start of hormonal therapy, and the follow-up spaced out to annual visits when stable. Side effects were asked at

Results

For the 141 women with CAIS in the study group, the median age of the women at their last attendance was 32 (16–69) years and age of diagnosis was 16 (0–38) years. The most common reason for diagnosis was primary amenorrhoea in 54% followed by hernia in childhood (29%) and family history of CAIS (16%). One woman presented with discordance in amniocentesis karyotype and birth phenotype. Past history of hernia was present in 59%, which was identified at age 1.5 (0.1–24) years.

Gonadectomy had been deferred indefinitely (n=13) or was pending (n=3) in 16/141 (11%). In the remainder, the age of gonadectomy was 17 (0.1–53) years.

The median age of initiation of HRT was 18 (8–41) years. Table 1 shows the HRT choices of the 141 women of whom 23 did not require HRT either because gonads were in situ or they had chosen to stop HRT either because of intolerance or because it was age appropriate. The most common form of HRT was some form of oestrogen in 113/141 (80%) of the total group or 96% or those requiring HRT. Vaginal oestrogens alone (n=1) or together...
with systemic sex steroids (n=12) were required in 13/141 (9%) women.

Testosterone was used in 14/141 (10%) of the total group or 12% of women requiring HRT with 8 women choosing to combine both oestrogen and testosterone treatments and 6 using testosterone alone. The median duration of use of testosterone was 4 (1–25) years. Most notable was an individual who used Nebido at full dose for 25 years with no side effects and well-maintained vitality. On review of past HRT experience, a further 10 individuals had used testosterone therapy in the past but had discontinued. The reason for discontinuing was almost universally that no meaningful benefit was perceived. No side effects to testosterone were recorded in routine clinic notes. Overall, therefore 24 (17%) women had used testosterone therapy at some time.

### Discussion

This study is the first to provide real-life data on the hormone treatment choices made by adult women with CAIS. Oestrogen was used by 96% of those using HRT and testosterone by 12%. Over half (58%) of women who had tried testosterone treatment chose to continue at the time of assessment.

The most common form of HRT in our study was oral oestrogen, followed by transdermal oestrogen. Advantages of transdermal over oral oestrogen formulations are well known, including a more physiologic mode of delivery, decrease hepatic first-pass effect and reduced risk of thromboembolism, but oral oestrogen is widely accepted by patients owing to the convenience of administration (5, 6). The dosage used was based empirically on clinical wellbeing reported by the patient. Individuals were offered a dose adjustment at each clinic visit with physician guidance and with reference to the bone mineral density (BMD) measurement. To assist women in making the decision, they are informed of their BMD result and the general rule was the higher dose of HRT of any kind is a benefit to bone density (7, 8). Local vaginal oestrogen was used by 9% of women, often prescribed as adjuvant therapy for those who require vaginal dilatation. Oestrogen implants were previously a popular choice but only a few users remained on implants at the time of this assessment as this form of treatment is not easily available in the United Kingdom.

A proportion of women with CAIS favoured the use of testosterone. This group of women were often previous users of oestrogen implants, which were an ideal option for women without a uterus who required an implant only every six months, eliminating the need for daily treatment. Intramuscular depot preparation of testosterone is a useful alternative requiring only 4 injections per year. In a small double-blind crossover study, there was no difference in psychosexual functioning in 4 women with CAIS using either androgen or oestrogen therapy for 4 weeks (9). A trial comparing the clinical and metabolic effects of testosterone and oestradiol in adult gonadectomised patients with 46,XY DSD due to CAIS is underway but results are not available yet (10). Our clinic experience leads us to conclude that controlled trials comparing oestrogen and testosterone would be extremely difficult because of the subtlety and imprecise quantification of outcome measures and because of the difficulty of blinding suitably high-dose preparations.

In a study among forty six 46,XY subjects with DSD, only 47.8% had an accurate diagnosis (11). With

---

**Table 1** Treatment choices of 141 women with CAIS.

<table>
<thead>
<tr>
<th>Type of HRT</th>
<th>n</th>
<th>%</th>
<th>Dose range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oestrogen</td>
<td>n</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Oral</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oestradiol valerate</td>
<td>59</td>
<td>41</td>
<td>1–6mg/24h</td>
</tr>
<tr>
<td>Conjugated equine oestrogen</td>
<td>12</td>
<td>8.5</td>
<td>0.2–1.875mg/24h</td>
</tr>
<tr>
<td>Transdermal oestradiol</td>
<td>41</td>
<td>29</td>
<td>25–300µg/24h</td>
</tr>
<tr>
<td>Vaginal oestradiol</td>
<td>13</td>
<td>9.2</td>
<td></td>
</tr>
<tr>
<td>Oestradiol implant</td>
<td>3</td>
<td>2.1</td>
<td></td>
</tr>
<tr>
<td>Testosterone</td>
<td>n</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transdermal testosterone</td>
<td>6</td>
<td>4.3</td>
<td>Testosterone 2% gel</td>
</tr>
<tr>
<td>Intramuscular testosterone</td>
<td>6</td>
<td>4.3</td>
<td>Testosterone undecanoate 1000mg</td>
</tr>
<tr>
<td>Oral testosterone</td>
<td>2</td>
<td>1.4</td>
<td>every 10–12 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Testosterone propionate 125–250mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>every 1–4 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Testosterone undecanoate 40–120mg</td>
</tr>
</tbody>
</table>

Note that each entry is not mutually exclusive with three individuals using combined oral and transdermal oestrogen, 12 women using vaginal oestrogen as a supplement to other sources and 8 using combined oestrogen and testosterone. With regard to testosterone, 5 women on transdermal and one on intramuscular used concurrent oestrogen.
of testosterone in CAIS, we could identify no theoretical or practical reason not to offer this option.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References
5 Stevenson JC. Type and route of estrogen administration. Climacteric 2009 12 (Supplement 1) 86–90. (doi:10.1080/13697130903007589)

Received in final form 12 June 2017
Accepted 14 June 2017
Accepted Preprint published online 14 June 2017